Pirfenidone yielded improved outcome over placebo in a trial of patients with progressive fibrotic interstitial lung diseases other than idiopathic pulmonary fibrosis (IPF). However, though the results were significant, the trial was terminated early due to slow recruitment, leaving the use of this agent in non-IPF fibrotic ILDs still in question. “Expert groups independent of ...
Pirfenidone may improve results for patients with non-IPF fibrotic ILDs: RELIEF
By Dave Levitan
7 Apr 2021